Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1951 1
1972 1
1977 1
1982 1
1983 3
1984 3
1985 2
1986 1
1990 2
1992 3
1993 3
1994 5
1995 2
1996 1
1997 5
1999 1
2000 4
2001 2
2002 2
2003 5
2005 3
2006 2
2007 4
2008 2
2009 4
2010 13
2011 6
2012 7
2013 6
2014 12
2015 17
2016 11
2017 7
2018 13
2019 9
2020 12
2021 8
2022 16
2023 14
2024 14
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

207 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R; TENAYA and LUCERNE Investigators. Khanani AM, et al. Ophthalmology. 2024 Aug;131(8):914-926. doi: 10.1016/j.ophtha.2024.02.014. Epub 2024 Feb 19. Ophthalmology. 2024. PMID: 38382813 Free article. Clinical Trial.
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Johnston SC, et al. N Engl J Med. 2018 Jul 19;379(3):215-225. doi: 10.1056/NEJMoa1800410. Epub 2018 May 16. N Engl J Med. 2018. PMID: 29766750 Free PMC article. Clinical Trial.
Osteocytes and Primary Cilia.
Verbruggen SW, Sittichokechaiwut A, Reilly GC. Verbruggen SW, et al. Among authors: reilly gc. Curr Osteoporos Rep. 2023 Dec;21(6):719-730. doi: 10.1007/s11914-023-00819-1. Epub 2023 Sep 8. Curr Osteoporos Rep. 2023. PMID: 37682373 Free PMC article. Review.
Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion: 72-Week Results from the BALATON and COMINO Trials.
Danzig CJ, Dinah C, Ghanchi F, Hattenbach LO, Khanani AM, Lai TYY, Shimura M, Abreu F, Arrisi P, Liu Y, Paris LP, Retiere AC, Willis JR, Schlottmann PG; BALATON and COMINO Investigators. Danzig CJ, et al. Ophthalmol Retina. 2025 Sep;9(9):848-859. doi: 10.1016/j.oret.2025.03.005. Epub 2025 Mar 17. Ophthalmol Retina. 2025. PMID: 40107501 Free article. Clinical Trial.
Trends in Mortality in People With HIV From 1999 through 2020: A Multicohort Collaboration.
Tusch E, Ryom L, Pelchen-Matthews A, Mocroft A, Elbirt D, Oprea C, Günthard HF, Staehelin C, Zangerle R, Suarez I, Vehreschild JJ, Wit F, Menozzi M, d'Arminio Monforte A, Spagnuolo V, Pradier C, Carlander C, Suanzes P, Wasmuth JC, Carr A, Petoumenos K, Borgans F, Bonnet F, De Wit S, El-Sadr W, Neesgaard B, Jaschinski N, Greenberg L, Hosein SR, Gallant J, Vannappagari V, Young L, Sabin C, Lundgren J, Peters L, Reekie J; D:A:D cohort study; RESPOND cohort study. Tusch E, et al. Clin Infect Dis. 2024 Nov 22;79(5):1242-1257. doi: 10.1093/cid/ciae228. Clin Infect Dis. 2024. PMID: 38663013 Free PMC article.
The frequency of pathogenic variation in the All of Us cohort reveals ancestry-driven disparities.
Venner E, Patterson K, Kalra D, Wheeler MM, Chen YJ, Kalla SE, Yuan B, Karnes JH, Walker K, Smith JD, McGee S, Radhakrishnan A, Haddad A, Empey PE, Wang Q, Lichtenstein L, Toledo D, Jarvik G, Musick A, Gibbs RA; All of Us Research Program Investigators. Venner E, et al. Commun Biol. 2024 Feb 19;7(1):174. doi: 10.1038/s42003-023-05708-y. Commun Biol. 2024. PMID: 38374434 Free PMC article.
Porous biomaterials for tissue engineering: a review.
Maksoud FJ, Velázquez de la Paz MF, Hann AJ, Thanarak J, Reilly GC, Claeyssens F, Green NH, Zhang YS. Maksoud FJ, et al. Among authors: reilly gc. J Mater Chem B. 2022 Oct 19;10(40):8111-8165. doi: 10.1039/d1tb02628c. J Mater Chem B. 2022. PMID: 36205119 Review.
GREENER principles for environmentally sustainable computational science.
Lannelongue L, Aronson HG, Bateman A, Birney E, Caplan T, Juckes M, McEntyre J, Morris AD, Reilly G, Inouye M. Lannelongue L, et al. Among authors: reilly g. Nat Comput Sci. 2023 Jun;3(6):514-521. doi: 10.1038/s43588-023-00461-y. Epub 2023 Jun 26. Nat Comput Sci. 2023. PMID: 38177425 Review.
207 results